PA5-58432

antibody from Invitrogen Antibodies

Targeting: FCHSD2 KIAA0769, SH3MD3

Western blot (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-58432

Provider

Invitrogen Antibodies

Product name

FCHSD2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: VEELSASENG DTPWMREIQI SPSPKPHASL PPLPLYDQPP SSPYPSPDKR SSLYFPRSPS ANEKSLHAES PGFSQASRHT PETSYGKLRP VRA Highest antigen sequence identity to the following orthologs: Mouse - 92%, Rat - 89%.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.1 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

FCHSD2 controls oncogenic ERK1/2 signaling outcome by regulating endocytic trafficking.

Xiao GY, Schmid SL
PLoS biology 2020 Jul;18(7):e3000778

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of FCHSD2 in Lane 1: Marker (kDa) 250, 130, 95, 72, 55, 36, 28, 17, 10; Lane 2: Human cell line RT-4. Samples were probed using a FCHSD2 Polyclonal Antibody (Product # PA5-58432).

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of FCHSD2 in human colon tissue shows strong cytoplasmic positivity in goblet cells. Samples were probed using a FCHSD2 Polyclonal Antibody (Product # PA5-58432).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig 6 FCHSD2 and Rab7 reciprocally regulate endocytic trafficking and lung cancer progression. (A) FCHSD2 regulates multiple steps in endocytic trafficking. We previously showed that activation of FCHSD2 downstream of ERK1/2 increases the rate of clathrin-coated pit initiation and CME in NSCLC cells. Here, we report that FCHSD2 also increases the fraction of RTK trafficking from early endosomes to recycling endosomes and negatively regulates Rab7 activity, maturation of late endosomes/multivesicular bodies, and trafficking to lysosomes. Together, these activities of FCHSD2 increase the flux of RTKs through early endocytic pathways, thus altering their downstream signaling. Loss of FCHSD2 results in the accumulation of RTKs in late endosomes/lysosomes, increases levels of activated ERK1/2 in the nucleus, and enhances transcription and expression of c-Jun, EGFR, and MET. (B) Immunohistochemistry images and quantification (expressed as H-score) of FCHSD2 staining in representative lung tumor tissues. Scale bar, 100 mum. Two-tailed Student t tests were used to assess statistical significance. ** P < 0.005, *** P < 0.0005. (C) Kaplan-Meier survival analysis of NSCLC or lung adenocarcinoma patients was performed in FCHSD2 or Rab7 high- and low-expression cohorts. The underlying data for this figure can be found in S1 Data . CCP, clathrin-coated pit; c-Jun, proto-oncogene c-Jun; CME, clathrin-mediated endocytosis; EE, early endosome; EGFR, epidermal growth factor receptor; ERK1/2, e